The anti-FcRH5/CD3 TDB is predicted to be broadly active in myeloma as the prevalence of the target expression is 100%, and as few as ∼200 copies of FcRH5 on a MM cell are sufficient to induce tumor cell killing. Here, FCRL5 is linked to neoplasm.